InflaRx GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public, Subsidiary
- Established
- 2007-12-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.inflarx.com
Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction
Phase 2
Completed
- Conditions
- Septic ShockSevere Sepsis
- Interventions
- Biological: CaCP29Biological: Placebo
- First Posted Date
- 2014-09-23
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- InflaRx GmbH
- Target Recruit Count
- 72
- Registration Number
- NCT02246595
- Locations
- 🇩🇪
Study Site, Oldenburg, Germany
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29
Phase 1
Completed
- Conditions
- Drug Safety
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- InflaRx GmbH
- Target Recruit Count
- 26
- Registration Number
- NCT01319903
- Locations
- 🇩🇪
FOCUS Clinical Drug Development GmbH, Neuss, Nordrhein-Westfalen, Germany
© Copyright 2025. All Rights Reserved by MedPath